Last reviewed · How we verify
Iodixanol 320
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures.
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures. Used for Radiographic contrast agent for coronary and peripheral angiography, Contrast agent for computed tomography imaging, Contrast agent for other diagnostic imaging procedures requiring vascular or organ visualization.
At a glance
| Generic name | Iodixanol 320 |
|---|---|
| Also known as | VISIPAQUE (TM) |
| Sponsor | Bracco Diagnostics, Inc |
| Drug class | Iso-osmolar contrast medium |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Iodixanol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. As an iso-osmolar contrast medium, it has an osmolality equal to blood plasma, which may reduce the risk of contrast-induced nephropathy compared to hyperosmolar agents. It is used intravenously to enhance visualization during angiography, CT, and other radiographic procedures.
Approved indications
- Radiographic contrast agent for coronary and peripheral angiography
- Contrast agent for computed tomography imaging
- Contrast agent for other diagnostic imaging procedures requiring vascular or organ visualization
Common side effects
- Contrast-induced nephropathy
- Hypersensitivity reactions
- Nausea and vomiting
- Flushing and warmth sensation
- Arrhythmias
Key clinical trials
- Intra-discal Steroid Injection for MODIC I Discopathy (PHASE4)
- Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material (PHASE4)
- Correlation Between Computer Tomography Angiography and D-Dimer Level for the Diagnosis of Pulmonary Embolism
- Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
- Kidney Damage in Patients With Moderate Fall in eGFR (PHASE4)
- A Low-dose Radiation and Contrast Agent Exposure Protocol for Coronary CTA in Diabetic Patients (NA)
- A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease (PHASE4)
- A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iodixanol 320 CI brief — competitive landscape report
- Iodixanol 320 updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI